ºñ¼Ò¼¼Æ÷¼º Æó¾Ï¿¡¼­ È£Èíµ¿±â¹æ»ç¼±Ä¡·á Àû¿ë ȯÀÚ±ºÀÇ ¼±ÅÃÀ» À§ÇÑ ¿¹ÃøÀÎÀÚµéÀÇ ºÐ¼®
The Analysis of Predictive Factors for the Identification of Patients Who Could Benefit from Respiratory-Gated Radiotherapy in Non-Small Cell Lung Cancer

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2009³â 27±Ç 4È£ p.228 ~ p.239

À强¼ø(Jang Sung-Soon) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç
¹ÚÁöÂù(Park Ji-Chan) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç

Abstract

¸ñÀû: ºñ¼Ò¼¼Æ÷¼º Æó¾Ï¿¡¼­ È£Èíµ¿±â¹æ»ç¼±Ä¡·áÀÇ À̵æÀ» Æò°¡ÇÏ°í ÀÌ·± Ä¡·á¹ýÀÇ Àû¿ëÀ¸·Î À̵æÀÌ ÀÖÀ» ȯÀÚµéÀ» ¼±ÅÃÇϱâ À§ÇÑ ¿¹ÃøÀÎÀÚµéÀ» ¼±Á¤Çϱâ À§ÇÏ¿© ¹æ»ç¼±Ä¡·á¸¦ À§ÇØ ½ÃÇàµÇ¾ú´ø 4-dimensional computed tomography (4DCT) ¿µ»óµéÀ» ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 15¸íÀÇ º´±â 1¡­3±â ºñ¼Ò¼¼Æ÷¼º Æó¾Ï ȯÀڵ鿡¼­ 3 Á¾·ùÀÇ ´Ù¸¥ °èȹ¿ëÇ¥ÀûüÀû(PTV)À» »ç¿ëÇÏ¿© Ä¡·á°èȹµéÀÌ ¼ö¸³µÇ¾ú´Ù. Áï PTVroutineÀº µ¿±ââ(gating window)ÀÇ Á߽ɿ¡ ÇØ´çµÇ´Â ´ÜÀÏ binÀÇ À°¾ÈÀûÁ¾¾çüÀû(GTV)¿¡ Åë»óÀûÀÎ ±ÕÀÏ marginÀ» Àû¿ëÇØ ±¸¼ºÇÏ¿´°í ȯÀÚ Æ¯ÀÌÀûÀÎ PTVall phases´Â È£ÈíÁֱ⠳» ¸ðµç 6 binsÀÇ º¹ÇÕ GTV·ÎºÎÅÍ ±¸¼ºµÇ¾ú´Ù. ±×¸®°í È£Èíµ¿±âÄ¡·á¿¡ »ç¿ëµÈ PTVgatingÀº È£±â¸»´Ü(end-exhalation)¿¡¼­ 3 ¿¬¼ÓÀûÀÎ binsÀÇ º¹ÇÕ GTV·ÎºÎÅÍ ±¸¼ºµÇ¾ú´Ù.

°á°ú: PTVroutine¿¡ ºñÇØ PTVall phases´Â 43.2%ÀÇ PTV °¨¼ÒÀ²À» ³ªÅ¸³Â°í, PTVgatingÀº PTVall phases¿Í ºñ±³Çؼ­ 9.5%ÀÇ Ãß°¡ÀûÀÎ PTV °¨¼ÒÀ²À» º¸¿´´Ù. PTVroutine°ú ºñ±³Çؼ­ PTVall phases¿Í PTVgatingÀÇ »ç¿ëÀº Æò±ÕÆó¼±·®(MLD)À» °¢°¢ 18.1%¿Í 21.6% °¨¼Ò½ÃÄ×°í V20Àº °¢°¢ 18.2%¿Í 22.0% °¨¼ÒµÇ¾ú´Ù. Á¾¾ç ¿òÁ÷ÀÓ°ú ¿ëÀû ºÐ¼®µéÀ» ÅëÇØ ¼±ÅÃµÈ 3D ¿òÁ÷ÀÓº¤ÅÍ, È£Èíµ¿±â·Î ÀÎÇÑ 3D ¿òÁ÷ÀÓÀÇ °¨¼ÒÅ©±â¿Í PTV °¨¼ÒÀ², ±×¸®°í µÎ ±Ø´ÜÀÇ È£Èí´Ü°è GTVµé °£¿¡ ¼­·Î Áߺ¹µÇ´Â ¿ëÀûÀÇ ºñÀ² °°Àº ¿¹ÃøÀÎÀÚµéÀº È£Èíµ¿±â·Î ÀÎÇÑ Ãß°¡ÀûÀÎ MLD, V20 °¨¼ÒÀ²µé°ú À¯ÀÇÇÑ »ó°ü¼ºÀ» º¸¿´´Ù.

°á·Ð: 4DCT¸¦ ÀÌ¿ëÇÑ È¯ÀÚ Æ¯ÀÌÀû PTVÀÇ »ç¿ë°ú ºñ±³Çؼ­ È£Èíµ¿±â·Î ÀÎÇÑ Ãß°¡ÀûÀÎ À̵æÀº Å©Áö ¾Ê¾ÒÀ¸³ª, ÀÌ·¯ÇÑ À̵æÀº ¿¹ÃøÀÎÀڵ鿡 µû¶ó ºÐ¸íÇÑ »ó°ü¼º°ú Â÷À̸¦ º¸¿´´Ù. ÀÌ·± ¿¹ÃøÀÎÀÚµéÀº È£Èíµ¿±â¹æ»ç¼±Ä¡·á¿¡ ÀûÇÕÇÑ È¯ÀÚµéÀ» ¼±ÅÃÇϱâ À§ÇØ À¯¿ëÇÒ °ÍÀÌ´Ù.
Purpose: 4DCT scans performed for radiotherapy were retrospectively analyzed to assess the possible benefits of respiratory gating in non-small cell lung cancer (NSCLC) and established the predictive factors for identifying patients who could benefit from this approach.

Materials and Methods : Three treatment planning was performed for 15 patients with stage I~III NSCLC using different planning target volumes (PTVs) as follows: 1) PTVroutine, derived from the addition of conventional uniform margins to gross tumor volume (GTV) of a single bin, 2) PTVall phases (patient-specific PTV), derived from the composite GTV of all 6 bins of the 4DCT, and 3) PTVgating, derived from the composite GTV of 3 consecutive bins at end-exhalation.

Results: The reductions in PTV were 43.2% and 9.5%, respectively, for the PTVall phases vs. PTVroutine and PTVgating vs. PTVall phases. Compared to PTVroutine, the use of PTVall phases and PTVgating reduced the mean lung dose (MLD) by 18.1% and 21.6%, and V20 by 18.2% and 22.0%, respectively. Significant correlations were seen between certain predictive factors selected from the tumor mobility and volume analysis, such as the 3D mobility vector, the reduction in 3D mobility and PTV with gating, and the ratio of GTV overlap between 2 extreme bins and additional reductions in both MLD and V20 with gating.

Conclusion: The additional benefits with gating compared to the use of patient-specific PTV were modest; however, there were distinct correlations and differences according to the predictive factors. Therefore, these predictive factors might be useful for identifying patients who could benefit from respiratory-gated radiotherapy.

Å°¿öµå

ºñ¼Ò¼¼Æ÷¼º Æó¾Ï, È£Èíµ¿±â¹æ»ç¼±Ä¡·á, 4DCT
Non-small cell lung cancer, Respiratory-gated radiotherapy, 4DCT
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
The predictive factors could be useful for identifying patients who could benefit from respiratory-gated radiotherapy.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå